Share >  
Share
Share on Tumblr

Uday Baldota

News »

   latest by relevance
Wyeth's claim on Protonix unjustified: Sun Pharma
Feb 16, 2012 at 11:35 | Source: CNBC-TV18
We strongly believe that we have reasons to disagree with the claim that they have made. Fundamentally, we also believe that the patent invalidated is something that we will continue to fight for, Uday Baldota, vice president - investor relations, Sun Pharma told CNBC-TV18.
Limited competition, Forex gains pump Taro nos: Sun Pharma
Nov 14, 2011 at 14:29 | Source: CNBC-TV18
In an interview to CNBC-TV18, Uday Baldota of Sun Pharma says the results of Taro, have been boosted by lack of competition and Forex gains. With 'very strong numbers' reported by Taro this quarter, Badola says its delisting process is still ongoing.
Merck JV will earn revenues in a few years, says Sun Pharma
May 30, 2011 at 16:48 | Source: CNBC-TV18
In an exclusive interview with CNBC-TV18, Uday Baldota of Sun Pharma says the company saw significant growth in Sun Pharmas standalone numbers, while as well "Taro reported strong margins this quarter." The leading drugmaker discloses that the company is "bearing additional costs for some non-revenue generating businesses."
Sun Pharma eyes revenue growth of 28-30% in FY12
May 30, 2011 at 12:24 | Source: CNBC-TV18
Sun Pharmaceutical is eyeing revenue growth of 28-30% in FY12, said Uday Baldota of Sun Pharma. In an interview to CNBC-TV18, Baldota said that Taro Pharmaceutical Industries reported strong margins this quarter.
Sun Pharma expects 35% sales growth this year
Nov 01, 2010 at 15:59 | Source: CNBC-TV18
In an interview with CNBC-TV18's Latha Venkatesh and Ekta Batra, Uday Baldota, vice president (investor relations) at Sun Pharma, spoke about the results and his outlook for the company.
Sun Pharma guides towards 20% rev growth in FY11
May 25, 2010 at 12:11 | Source: CNBC-TV18
Commenting on the Sun Pharma's guidance for FY11, its Managing Director Uday Baldota said that the guidance took into account the growth in different business segments. "And, all segments, except US generics, have shown growth."

Videos »
Wyeth's claim on Protonix unjustified: Sun Pharma
Limited competition, Forex gains pump Taro nos: Sun Pharma
Merck JV will earn revenues in a few years, says Sun Pharma
Sun Pharma eyes revenue growth of 28-30% in FY12
Sun Pharma expects 35% sales growth this year
more »

Photos »

  /  
Interact & exchange stock tips & market info »

NEWS786

Platinum Member

175 Followers

Sun Pharma  

Sun Pharma says won`t revise taro offer price MUMBAI: Mumbai-based S...

11.00 AM Mar 18th

Related News »
Plavix Set to Lose Patent Protection
Uday Baldota, a spokesman for Sun Pharmaceutical Industries, an Indian drug maker that has received tentative approval to sell generic Plavix, said his company often planned for the introduction of a new drug seven to eight years ahead of time ...
May 17, 2012 at 04:03 | Source: New York Times
IsZo Capital Calls upon Special Committee of Taro Pharmaceutical to Reject Immediately Nearly 7-Mont
An increased offer price by Sun? Uday Baldota, Senior Vice President, Investor Relations, of Sun was cited as recently as March 15, 2012 by The Economic Times stating that Sun has no intention of increasing its offer price for Taro's shares. What is most ...
May 9, 2012 at 23:53 | Source: PR-USA.net

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window